NeuroNEXT at SNI

NeuroNEXT at Swedish Neuroscience Institute (SNI) is one of only two Pacific Northwest sites for a nationwide consortium of 25 centers that conducts clinical trials for patients with diseases of the nervous system. The NeuroNEXT consortium is sponsored by the National Institute of Neurological Disorders and Stroke. The Site Principal Investigator for all NeuroNEXT studies here at Swedish is Dr. James Bowen.

New and Ongoing NeuroNEXT Clinical Trials at SNI

NN105 STAIR: “Tolerability, Safety, and Activity of SRX246 in Irritable Subjects with Huntington’s Disease”
is just about ready to open. Irritability is common in patients with Huntington’s Disease (HD). Irritability is defined as episodic, periodic, or chronic internal feelings of anxiety, impatience, or anger that can be expressed externally by behaviors such as being short-tempered, impulsive, impatient, volatile, hostile, agitated, angry, or several other similar behaviors. Although there are some therapies available to help treat these HD symptoms, on a few small clinical trials have been done on the effectiveness of available treatments.

The NN105 study will test a drug called SRX246 for tolerability in HD patients with irritability. The study will enroll just over 100 patients at 20 NeuroNEXT sites, including at SNI. Azevan Pharmaceuticals, Inc., is providing the study medication.  Principal Investigator Dr. Rosalind Chuang and Neuroscience Research staff members will attend the Investigators Meeting in March 2016. We hope to open this study by mid-2016. 

For information on this study contact Study Coordinator Caryl Tongco at 206-215-3565 or by email at you can also contact Site Coordinator Becky Wood at 206-320-7115 or by email at Information about this study can also be found on Search for study number NCT02507284.

NN103 BeatMG: “A Phase II Trial of Rituximab in Myasthenia Gravis” is nearing its enrollment goal. Swedish Principal Investigator Dr. Eric Gierke has screened a total of twelve patients for this study, which looks at the safety, tolerability, and effectiveness of rituximab for people with myasthenia gravis (MG). Results of this study hopefully will show that this drug will allow MG patients to decrease their prednisone dosage or even discontinue prednisone treatment. For information on this study contact Site Coordinator Becky Wood at 206-320-7115 or by email at Information about this study can also be found on Search for study number NCT02110706.

NN102 SPRINT-MS: The SPRINT-MS study, “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis,” closed for enrollment in mid-2015 after reaching its enrollment goal of 250 subjects. Dr. Pavle Repovic and the research team at the MS Center at SNI enrolled a total of 10 subjects, with 7 people continuing into the study and 3 screen fails. Current enrolled study participants will continue with study visits with the last patient, last visit occurring in late fall 2017.

NeuroNEXT News

The 2016 Research Investigator Training education component is going to take a different approach this year. Although our past Research Investigator Training Symposia have been quite successful, we are going to offer research training to the Neuroscience and Neurosurgery Residents and Fellows at Swedish Neuroscience Institute. The course will focus on the fundamentals of clinical research and provide information on the foundations of trial design, IRB review, data collection, sample collection, humans subjects protection, and many other general topics of designing and running a clinical trial.